Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction.

Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. Eur Heart J (2014) 1.74

Coronary pressure-derived fractional flow reserve in the assessment of coronary artery stenoses. Eur Radiol (2012) 0.87

Recent advances in the diagnosis and treatment of acute myocardial infarction. World J Cardiol (2015) 0.85

Fractional flow reserve versus angiography in guiding management to optimize outcomes in non-ST-elevation myocardial infarction (FAMOUS-NSTEMI): rationale and design of a randomized controlled clinical trial. Am Heart J (2013) 0.84

Improvement in coronary haemodynamics after percutaneous coronary intervention: assessment using instantaneous wave-free ratio. Heart (2013) 0.83

Safety of guidewire-based measurement of fractional flow reserve and the index of microvascular resistance using intravenous adenosine in patients with acute or recent myocardial infarction. Int J Cardiol (2015) 0.79

Comprehensive assessment of coronary fractional flow reserve. Arch Med Sci (2015) 0.78

Left ventricular end-diastolic pressure affects measurement of fractional flow reserve. Cardiovasc Revasc Med (2013) 0.78

Percutaneous treatment in acute coronary syndromes. World J Cardiol (2011) 0.78

Current Status of Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease. Korean Circ J (2014) 0.77

Association of Lower Fractional Flow Reserve Values With Higher Risk of Adverse Cardiac Events for Lesions Deferred Revascularization Among Patients With Acute Coronary Syndrome. J Am Heart Assoc (2015) 0.77

Fractional flow reserve: a new set of lenses for the occulostenotic reflex? JACC Cardiovasc Interv (2010) 0.77

Clinical and Angiographic Predictors of Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction. Yonsei Med J (2015) 0.77

Management of Multivessel Coronary Disease in ST-segment Elevation Myocardial Infarction. Curr Cardiol Rep (2015) 0.75

Culprit lesion-only versus complete revascularization in patients with STEMI: Lessons learned from PRAMI, CvLPRIT, and DANAMI-3 PRIMULTI. Glob Cardiol Sci Pract (2015) 0.75

Fractional flow reserve measurements to identify justified targets for PCI in patients with stable angina: FAME 2 and beyond. Cardiovasc Diagn Ther (2012) 0.75

Optimal Timing of Percutaneous Coronary Intervention for Nonculprit Vessel in Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Disease. Korean Circ J (2016) 0.75

Role of coronary physiology in the contemporary management of coronary artery disease. World J Clin Cases (2015) 0.75

Immediate multivessel revascularization may increase cardiac death and myocardial infarction in patients with ST-elevation myocardial infarction and multivessel coronary artery disease: data analysis from real world practice. Korean J Intern Med (2016) 0.75

Physiologic approach for coronary intervention. Korean J Intern Med (2012) 0.75

Rapid progression of nonculprit coronary lesions six weeks after successful primary PCI in culprit artery: a case report. J Biomed Res (2014) 0.75

Clinical Relevance of Coronary Fractional Flow Reserve: Art-of-state. Chin Med J (Engl) (2015) 0.75

Fractional Flow Reserve in Acute Myocardial Infarction: A Guide for Non-Culprit Lesions? Cardiol Ther (2015) 0.75

Fine-tuning treatment for patients with ST-elevation myocardial infarction. J Thorac Dis (2016) 0.75

Culprit-only versus staged complete revascularization for patients with ST-segment elevation myocardial infarction and Multivessel disease: a retrospective cohort study. BMC Cardiovasc Disord (2016) 0.75

Fractional flow reserve of non-culprit vessel post-myocardial infarction: is it reliable? BMC Cardiovasc Disord (2015) 0.75

Staged re-evaluation of non-culprit lesions in ST segment elevation myocardial infarction: a retrospective study. Open Heart (2016) 0.75

Complex Coronary Hemodynamics - Simple Analog Modelling as an Educational Tool. Open Med Inform J (2017) 0.75

Evaluation of intermediate coronary stenoses in acute coronary syndromes using pressure guidewire. Open Heart (2017) 0.75

Reperfusion strategies in acute myocardial infarction and multivessel disease. Nat Rev Cardiol (2017) 0.75

Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med (2009) 13.42

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J (2011) 13.10

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73

Universal definition of myocardial infarction. Circulation (2007) 11.69

2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J (2014) 9.73

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54

Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85

Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59

Third universal definition of myocardial infarction. Circulation (2012) 8.47

Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med (2012) 8.39

Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98

Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51

2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J (2013) 6.17

Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol (2010) 5.63

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J (2013) 5.23

Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol (2013) 5.11

Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol (2007) 5.02

Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2003) 4.70

Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet (2003) 4.68

Relationship between noninvasive coronary angiography with multi-slice computed tomography and myocardial perfusion imaging. J Am Coll Cardiol (2006) 4.37

Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med (2014) 4.37

Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation (2007) 4.24

Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47

Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol (2010) 2.89

DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. Eur Heart J (2004) 2.85

Fractional flow reserve assessment of left main stenosis in the presence of downstream coronary stenoses. Circ Cardiovasc Interv (2013) 2.71

Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol (2008) 2.68

Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J (2009) 2.68

Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet (2011) 2.67

Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ (2014) 2.62

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation (2008) 2.62

Assessment of renal artery stenosis severity by pressure gradient measurements. J Am Coll Cardiol (2006) 2.61

Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet (2008) 2.57

Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care** and Thrombosis of the European Society of Cardiology. EuroIntervention (2013) 2.48

Does the instantaneous wave-free ratio approximate the fractional flow reserve? J Am Coll Cardiol (2013) 2.39

Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation (2005) 2.35

Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J (2005) 2.29

Prognostic value of coronary blood flow velocity and myocardial perfusion in intermediate coronary narrowings and multivessel disease. J Am Coll Cardiol (2002) 2.18

Physiological assessment of coronary artery disease in the cardiac catheterization laboratory: a scientific statement from the American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology. Circulation (2006) 2.18

Frequency of abdominal aortic aneurysm in patients >60 years of age with coronary artery disease. Am J Cardiol (2005) 2.13

Cost-effectiveness of percutaneous coronary intervention in patients with stable coronary artery disease and abnormal fractional flow reserve. Circulation (2013) 2.13

Evaluation of plaque characteristics in acute coronary syndromes: non-invasive assessment with multi-slice computed tomography and invasive evaluation with intravascular ultrasound radiofrequency data analysis. Eur Heart J (2008) 2.13

Fractional flow reserve and myocardial perfusion imaging in patients with angiographic multivessel coronary artery disease. JACC Cardiovasc Interv (2010) 2.08

In vitro and in vivo studies on thermistor-based intracoronary temperature measurements: effect of pressure and flow. Catheter Cardiovasc Interv (2009) 2.04

Meta-analysis of comparative diagnostic performance of magnetic resonance imaging and multislice computed tomography for noninvasive coronary angiography. Am Heart J (2006) 2.02

Functional SYNTAX score for risk assessment in multivessel coronary artery disease. J Am Coll Cardiol (2011) 2.02

Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation (2005) 2.00

Improvement of left ventricular function after cardiac resynchronization therapy is predicted by tissue Doppler imaging echocardiography. Circulation (2004) 2.00

Direct stenting versus direct stenting followed by centered beta-radiation with intravascular ultrasound-guided dosimetry and long-term anti-platelet treatment: results of a randomized trial: Beta-Radiation Investigation with Direct Stenting and Galileo in Europe (BRIDGE). J Am Coll Cardiol (2004) 1.98

Bivalirudin use and one-month outcome in the context of contemporary antiplatelet treatment: insights from the Greek Antiplatelet Registry. Cardiovasc Ther (2014) 1.98

Diagnostic performance of multidetector CT angiography for assessment of coronary artery disease: meta-analysis. Radiology (2007) 1.97

Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007. EuroIntervention (2009) 1.94

Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. Circulation (2010) 1.92

The dynamic nature of coronary artery lesion morphology assessed by serial virtual histology intravascular ultrasound tissue characterization. J Am Coll Cardiol (2010) 1.90

Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J (2013) 1.90

Head-to-head comparison of coronary plaque evaluation between multislice computed tomography and intravascular ultrasound radiofrequency data analysis. JACC Cardiovasc Interv (2008) 1.86

Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation (2002) 1.82

Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet (2012) 1.80

Pathophysiology and treatment for cervical flexion myelopathy. Eur Spine J (2002) 1.79

The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol (2002) 1.78

Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology. Eur Heart J (2004) 1.77

Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med (2010) 1.70

2014 ESC/EACTS guidelines on myocardial revascularization. Rev Esp Cardiol (Engl Ed) (2015) 1.69

Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. Circ Cardiovasc Interv (2008) 1.66

On the inappropriateness of noninvasive multidetector computed tomography coronary angiography to trigger coronary revascularization: a comparison with invasive angiography. JACC Cardiovasc Interv (2009) 1.66

Acute myocardial infarction and underlying stenosis severity. Catheter Cardiovasc Interv (2007) 1.66

Fractional flow reserve-guided versus angiography-guided coronary artery bypass graft surgery. Circulation (2013) 1.65

Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation (2005) 1.64

One year follow-up of the multi-centre European PARTNER transcatheter heart valve study. Eur Heart J (2010) 1.63

Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation (2006) 1.62